Abiopharma

CURRENCY EXCHANGE INTERNATIONAL CORP (CURN)

Symbol	CURN
Name	CURRENCY EXCHANGE INTERNATIONAL CORP
Sector	UNDEFINED
Region	North America
Industry	-
Address	32821 United States FL 6649 Westwood Boulevard Suite 250
Telephone	+1 8889983948
Fax	—
Email	—
Website	http://www.ceifx.com
Incorporation	US
Incorporated On	1998
Employees	—
Fiscal Year	10/31
Public Since	—
Exchanges	OTC
Auditor	Grant Thornton LLP;
Audit Status	AUDITED
Reporting Status	Alternative Reporting Standard
CIK	0001448167
Description	Currency Exchange International is in the business of providing comprehensive foreign exchange technology and processing services for banks, credit unions, businesses, and consumers in the United States and select clients globally. Primary products and services include the exchange of foreign currencies, wire transfer payments, Global EFTs, and foreign cheque clearing. Wholesale customers are served through its proprietary FX software applications delivered on its web-based interface, www.cxifx.com ("CXIFX"), its related APIs with core banking platforms, and through personal relationship managers. Consumers are served through Group-owned retail branches, agent retail branches, and its e-commerce platform, order.ceifx.com ("OnlineFX"). Additional info from OTC: Currency Exchange International is in the business of providing comprehensive foreign exchange technology and processing services for banks, credit unions, businesses, and consumers in the United States and select clients globally. Primary products and services include the exchange of foreign currencies, wire transfer payments, Global EFTs, and foreign cheque clearing. Wholesale customers are served through its proprietary FX software applications delivered on its web-based interface, www.cxifx.com ("CXIFX"), its related APIs with core banking platforms, and through personal relationship managers. Consumers are served through Group-owned retail branches, agent retail branches, and its e-commerce platform, order.ceifx.com ("OnlineFX").

2026-03-24 17:31

Curatis: aumento dei ricavi a doppie cifre nel 2025 e raggiungimento di importanti traguardi per corticorelin

2026-03-24 17:31

Curatis: dubbelcijferige omzetgroei in 2025 en belangrijke mijlpalen voor corticorelin verwezenlijkt

2026-03-24 17:30

Curatis: Zweistelliges Umsatzwachstum im Jahr 2025 sowie wichtige Meilensteine für Corticorelin erreicht

2026-03-24 17:30

Curatis: aumento de ingresos de dos dígitos en 2025 y obtención de importantes hitos gracias a corticorelina

2026-03-24 17:30

Curatis : croissance à deux chiffres du chiffre d’affaires en 2025 et franchissement d’étapes importantes pour la corticoréline

2026-03-24 06:00

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved

2026-03-11 18:13

Curatis et Neupharma annoncent la signature d’un accord de licence exclusive pour le développement et la commercialisation au Japon du corticoréline (C-PTBE-01) dans le traitement de l’œdème cérébral péritumoral

2026-03-11 18:06

Curatis und Neupharma geben exklusive Lizenzvereinbarung zur Entwicklung und Vermarktung von Corticorelin (C-PTBE-01) zur Behandlung von peritumoralem Hirnödem in Japan bekannt

2026-03-11 18:02

Curatis y Neupharma anuncian un acuerdo de licencia exclusiva para desarrollar y comercializar en Japón la corticorelina (C-PTBE-01) para el tratamiento del edema cerebral peritumoral

2026-03-11 17:59

Curatis e Neupharma annunciano un accordo di licenza esclusiva per sviluppare e commercializzare corticorelin (C-PTBE-01) per il trattamento delledema cerebrale peritumorale in Giappone